Global Bispecific Antibody Market 2019:Industry Analysis By AstraZeneca, Xencor, Sanofi, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Eli Lilly and Company & Others

Global bispecific antibody market is expected to grow at a growing CAGR in the forecast period of 2019-2026. Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling the market growth.

The bispecific antibody report encompasses thorough analysis of market with respect to several factors about pharmaceutical industry that range from market drivers, market restraints, market segmentation, opportunities, challenges, and market revenues to competitive analysis. The report presents you with the CAGR value fluctuations for the specific forecasted period which helps decide costing and investment strategies. For market segmentation study, a market of potential customers is divided into groups or segments based on different characteristics such as end user and geographical region. This bispecific antibody market report brings to you precise and exact market research information that drives your business into the right direction.

Ask For Complimentary Sample PDF| Request At

Competitive Analysis:

Global bispecific antibody market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares global bispecific antibody market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

Few of the major competitors currently working in the global bispecific antibody market are Adimab, Innovent Biologics, Inc, Affimed GmbH, Amgen Inc, AstraZeneca, Xencor, Sanofi, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Eli Lilly and Company, Xencor, Pieris Pharmaceuticals, Inc, Mereo BioPharma Group plc, Sobi, TG Therapeutics, Inc, Merus, MacroGenics, Inc, Genmab A/S, Emergent BioSolutions Inc, Alteogen, Astellas Pharma Inc, Novartis AG, CELGENE CORPORATION and others.

Key Developments in the Market:

  • In April 2019, Innovent Biologics, Inc in collaboration with Eli Lilly and Company initiated phase I trial of IBI318, a recombinant fully human IgG1 bispecific antibody targeting PD-1 and PD-L1 for the treatment of advanced malignancies. If trial successful, it will change the treatment landscape and improve the lives of millions of patients suffering from advanced malignancies.
  • In June 2019, Regeneron Pharmaceuticals Inc reported topline positive results of REGN1979, a bispecific monoclonal antibody that targets B-cell tumor protein (CD20) and an immune system T-cell receptor (CD3) is developing for the treatment of relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma. The trial demonstrated, 93% overall response (13 of 14 patients) and 71% complete response rates. If trial successful, expanding their market share and emphasizing their superiority.

Get Full Table Of content @

Segmentation: Global Bispecific Antibody Market

By Type

  • Immunoglobulin G (IgG) Like Molecule
  • Non Immunoglobulin G (IgG) Like Molecule

By Mechanism of Action

  • Bispecific Diabodies
  • Bispecific T-Cell Engager Antibodies

By Application

  • Oncology
  • Autoimmune Disease
  • Others

By Drugs

  • Blinatumomab
  • Catumaxomab
  • Duligotumab
  • Others

By Route of Administration

  • Oral
  • Injectable

By End Users

  • Hospitals
  • Specialty Clinics
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies

By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Market Drivers

  • Ongoing clinical trial  conducted by many pharmaceuticals industries is propelling the growth of this market
  • Increase in special designation from the regulatory authorities is boosting the market growth
  • Major advancements in linker technology is likely to drive the market
  • High demand of disease specific novel treatment can also act as a market driver
  • The competitive scenario of market and strategic collaborations may boost the market position

Market Restraints

    • Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
    • Low healthcare budget in some developing countries is hamper the market growth
    • Patent expiration of branded drugs and introduction of generics is also hinders the market growth

Inquiry For Customize Report With Discount at :

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Data Bridge Market Research
Tel: +1-888-387-2818
Email: [email protected]